Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world.

Will gene therapies finally be commercially viable to pharma?

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when attempting to develop this technology. We review gene therapy’s chequered past, look at recent developments in this field and consider the future for gene therapies on their way to market.

Genes are segments of DNA which code instructions for your cells to make proteins. Many inherited disorders are a result of faulty genes which encode incorrect instructions for making specific proteins, either the proteins themselves are defective or the gene may have faulty expression which can result in over-expression so over-production of a certain kind of protein. In the case of cancer, there can be multiple external and internal factors which lead to production of genetically mutated cancerous cells.

read more »

  • Posted by Rachel Howard
  • July 16, 2015
  • Articles

China: The Future Of Pharmaceutical Industry Innovation?

China: The Future Of Pharmaceutical Industry Innovation?

Published in Medical Marketing & Media, July 2015

I recently visited a London art gallery in which one of the so-called Old Masters had been replaced by a “Made in China” replica. The gallery invited members of the public to try to identify which painting was not authentic. Although in the West replica art is typically denigrated as “fake,” perceptions are very different in China, where such art is considered aspirational. The exhibition made me think about the parallels between the art world and the pharmaceutical industry, in terms of perceptions of Chinese-made drugs versus Big Pharma.
The most obvious parallel to draw would be counterfeit pharmaceuticals originating from China. This is a business globally estimated by WHO to be worth $75 billion US dollars a year and rising. Counterfeit drugs are a huge problem in emerging markets and China is no exception. Outside of the art world, the country already has a long-standing reputation for producing inferior and counterfeit goods, from imitation Louis Vuitton bags to copycat smart phones.

read more »